P1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000848836.01685.87 |
| _version_ | 1827335073092861952 |
|---|---|
| author | S. Saraf R. C. Brown R. W. Hagar M. Idowu I. Osunkwo T. A. Kalfa F. A. Kuypers J. Geib P. Schroeder E. Wu P. Kelly M. J. Telen |
| author_facet | S. Saraf R. C. Brown R. W. Hagar M. Idowu I. Osunkwo T. A. Kalfa F. A. Kuypers J. Geib P. Schroeder E. Wu P. Kelly M. J. Telen |
| author_sort | S. Saraf |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:09:21Z |
| format | Article |
| id | doaj.art-262dc9b8e6cf4b478ba5910bcd26a386 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:09:21Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-262dc9b8e6cf4b478ba5910bcd26a3862024-03-02T07:47:31ZengWileyHemaSphere2572-92412022-06-0161377137810.1097/01.HS9.0000848836.01685.87202206003-01377P1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTHS. Saraf0R. C. Brown1R. W. Hagar2M. Idowu3I. Osunkwo4T. A. Kalfa5F. A. Kuypers6J. Geib7P. Schroeder8E. Wu9P. Kelly10M. J. Telen111 University of Illinois at Chicago, Chicago2 Children’s Healthcare of Atlanta, Atlanta3 UCSF Benioff Children’s Hospital San Francisco, Oakland4 UTHealth McGovern Medical School, Houston5 Levine Cancer Institute, Charlotte6 Cincinnati Children’s Hospital Medical Center, Cincinnati7 University of California, San Francisco8 Forma Therapeutics, Inc., Watertown8 Forma Therapeutics, Inc., Watertown8 Forma Therapeutics, Inc., Watertown8 Forma Therapeutics, Inc., Watertown9 Duke University Medical Center, Durham, United States of Americahttp://journals.lww.com/10.1097/01.HS9.0000848836.01685.87 |
| spellingShingle | S. Saraf R. C. Brown R. W. Hagar M. Idowu I. Osunkwo T. A. Kalfa F. A. Kuypers J. Geib P. Schroeder E. Wu P. Kelly M. J. Telen P1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH HemaSphere |
| title | P1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH |
| title_full | P1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH |
| title_fullStr | P1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH |
| title_full_unstemmed | P1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH |
| title_short | P1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH |
| title_sort | p1495 etavopivat treatment for up to 12 weeks in patients with sickle cell disease is well tolerated and improves red blood cell health |
| url | http://journals.lww.com/10.1097/01.HS9.0000848836.01685.87 |
| work_keys_str_mv | AT ssaraf p1495etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT rcbrown p1495etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT rwhagar p1495etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT midowu p1495etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT iosunkwo p1495etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT takalfa p1495etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT fakuypers p1495etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT jgeib p1495etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT pschroeder p1495etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT ewu p1495etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT pkelly p1495etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT mjtelen p1495etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth |